Common Stock, par value $0.01 per share
- Symbol
- IRIX
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
IRIDEX Corporation
IRIXNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On January 12, 2026, IRIDEX Corporation (the "Company") announced its preliminary, unaudited operational and financial results for its fourth fiscal quarter and full fiscal year ended January 3, 2026. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.…
Company context
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, which include capital equipment and consumable probes for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers the therapeutic benefits of laser treatment while minimizing tissue damage, offering a safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
Current securities
Recent company filings
- 4 filingSep 16, 2026
- Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingSep 2, 2026
- 10-Q filingAug 18, 2026
- Results of Operations and Financial ConditionAug 18, 2026
- Submission of Matters to a Vote of Security Holders · Regulation FD DisclosureJul 16, 2026
Registered securities in this filing
IRIDEX CORPORATION · 8-K · Filed 2026-01-12
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02. Results of Operations and Financial Condition.
On January 12, 2026, IRIDEX Corporation (the "Company") announced its preliminary, unaudited operational and financial results for its fourth fiscal quarter and full fiscal year ended January 3, 2026. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Filed exhibits (1)
EX-99.1 2 irix-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025 Demonstrating continued revenue growth, operational efficiencies and positive cash flow MOUNTAIN VIEW, Calif., Jan. 12, 2026 - Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the fourth quarter and full year ended January 3, 2026. Fourth Quarter 2025 Results • Total revenue is expected to be between $14.6 million and $14.8 million compared to $12.7 million in the prior year quarter, representing year-over-year growth between 15% and 17% • Achieved positive cash flow in the fourth quarter • Sold 15,800 Cyclo G6® probes compared to 13,300 in the prior year quarter • Sold 44 Cyclo G6 Glaucoma Laser Systems, compared to 47 in the prior year quarter Full Year 2025 Results • Total revenue is expected to be between $52.5 million and $52.7 million compared to $48.7 million in 2024, represe…
Open exhibit ↗